Midatech Pharma plc (MTPH.L) Comparison with companies in other sectors?

Midatech Pharma plc has a share price of 173.35M. You can analyze Midatech Pharma plc (MTPH.L) competitors across different market sectors through stock heatmaps.

What are MTPH.L's NET and operating margins?

Midatech Pharma plc (MTPH.L) operating margin is around -12.78, and net profit margin is approximately -10.95 as of the latest reports.

In what way does MTPH.L's earnings per share (EPS) trend reflect its financial momentum?

Midatech Pharma plc (MTPH.L) EPS is -0.82 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Midatech Pharma plc is -0.22, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Midatech Pharma plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Midatech Pharma plc like P/E which is 0.00, P/B which is 0.00, and PEG which is 0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Midatech Pharma plc

MTPH.L•LSE

Healthcare

Biotechnology

£18.00

£17.05(1794.74%)

Fundamental Analysis of Midatech Pharma plc (MTPH.L)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.82

P/E Ratio

-0.22

ROE

-1.12%

Net Margin

-10.95%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$31.20M

Shares OutstandingTotal number of shares issued

$173.35M

Book Value/ShareNet worth per share

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.82

Net MarginNet income as percentage of revenue

-1095.28%

Operating MarginOperating income as percentage of revenue

-1277.83%

ROEReturn on shareholders' equity

-112.47%

ROAReturn on total assets

-138.57%

ROCEReturn on capital employed

-246.40%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

FCF YieldFree cash flow as percentage of market cap

-22.79%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for MTPH.LFinancial Ratios Analysis details for MTPH.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for MTPH.LSector Benchmarking details for MTPH.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Midatech Pharma plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Midatech Pharma plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Midatech Pharma plc's unique business strengths and challenges.

Key Financial Metrics for Midatech Pharma plc

For Midatech Pharma plc, essential financial indicators include EPS -0.82, PE -0.22, and ROE -1.12. These key ratios reveal insights into Midatech Pharma plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Midatech Pharma plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Midatech Pharma plc

Metrics like Net Margin -1095.28% and ROA -138.57% shed light on how well Midatech Pharma plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Midatech Pharma plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Midatech Pharma plc

Using ratios such as P/B Ratio - and PEG Ratio -, investors can assess whether Midatech Pharma plc is appropriately valued based on its financials and growth potential. These figures, combined with Midatech Pharma plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Midatech Pharma plc

Financial health indicators, such as Debt/Equity Ratio 0.20 and Cash Flow -, provide a snapshot of Midatech Pharma plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Midatech Pharma plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Midatech Pharma plc

Investing in Midatech Pharma plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Midatech Pharma plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;